# US 2025/0205154 A1 · Liquid formulation pharmaceutical composition comprising plasmid dna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205154 A1
- Document ID: US20250205154A1
- Status: Published application
- Kind: A1
- Application number: 18/849,175
- Filed: 2022-12-01
- Published: 2025-06-26
- Earliest claimed: 2022-03-24
- Assignees: Helixmith Co., Ltd
- Applicants: Helixmith Co., Ltd
- Inventors: Kyungdong BAE; Yunyeol JO; Jihwan PARK
- Web page: https://patentgrep.com/patent/US20250205154A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 48/0016: {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a liquid formulation pharmaceutical composition comprising plasmid DNA. The liquid formulation comprising plasmid DNA according to the present invention shows excellent efficacy in terms of storage stability of plasmid DNA, which is a pharmaceutically active ingredient, and accordingly, can be useful as a pharmaceutical composition with excellent product stability and safety.

## Claims

### Claim 1

A liquid formulation of plasmid DNA, comprising 30-50 mM potassium phosphate, 0.5-1.5% NaCl, and plasmid DNA, with a pH of 7.5-8.5.

### Claim 2 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, wherein the liquid formulation comprises 40 mM potassium phosphate.

### Claim 3 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, wherein the liquid formulation comprises 0.9% NaCl.

### Claim 4 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, wherein the liquid formulation has a pH of 8.0.

### Claim 5 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, wherein the plasmid DNA in the liquid formulation maintains 80-100 SC % (supercoiled %) after storage at 20-30° C. for 6 months.

### Claim 6 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, further comprising sucrose, trehalose, mannitol, sorbitol, leucine, or a combination thereof.

### Claim 7 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, further comprising 1-2% of sucrose, 0.5-2% of trehalose, 0.01-1% of sorbitol, 0.05-0.5% of leucine, or a combination thereof.

### Claim 8 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, wherein the plasmid DNA is present at a concentration of 0.01-5 mg/mL.

### Claim 9 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, further comprising 0.15-1.5% of mannitol.

### Claim 10 (depends on 9)

The liquid formulation of plasmid DNA according to claim 9, wherein the plasmid DNA in the liquid formulation maintains 90-100 SC % after storage at 2-8° C. for at least 6 months.

### Claim 11 (depends on 9)

The liquid formulation of plasmid DNA according to claim 9, wherein the plasmid DNA in the liquid formulation maintains 60-100 SC % after storage at 15-30° C. for at least 3, 4, 5, or 6 months.

### Claim 12 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, further comprising 0.001-0.3% of mannitol, 0.05-0.5% of sorbitol, 0.05-0.5% of sucrose, 0.15-3% of trehalose, 0.01-1% of leucine, or a combination thereof.

### Claim 13 (depends on 12)

The liquid formulation of plasmid DNA according to claim 12, wherein the plasmid DNA in the liquid formulation maintains 90-100 SC % after storage at 2-8° C. for at least 3, 4, 5, 6, 7, 8, or 9 months.

### Claim 14 (depends on 12)

The liquid formulation of plasmid DNA according to claim 12, wherein the plasmid DNA in the liquid formulation maintains 80-100 SC % after storage at 20-30° C. for at least 3, 4, 5, 6, 7, 8, or 9 months.

### Claim 15 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, further comprising 0.001-0.3% of mannitol, 0.05-0.5% of sorbitol, 0.05-0.5% of sucrose, 0.15-3% of trehalose, 0.045-0.055% of leucine, or a combination thereof.

### Claim 16 (depends on 15)

The liquid formulation of plasmid DNA according to claim 15, wherein the liquid formulation comprises 37-37.3 mM potassium phosphate.

### Claim 17 (depends on 15)

The liquid formulation of plasmid DNA according to claim 15, wherein the liquid formulation comprises 0.975-1.0% of NaCl.

### Claim 18 (depends on 15)

The liquid formulation of plasmid DNA according to claim 15, wherein the plasmid DNA in the liquid formulation maintains 90-100 SC % after storage at 2-8° C. for at least 3, 4, 5, 6, 7, 8, or 9 months.

### Claim 19 (depends on 15)

The liquid formulation of plasmid DNA according to claim 15, wherein the plasmid DNA in the liquid formulation maintains 80-100 SC % after storage at 20-30° C. for at least 3, 4, 5, 6, 7, 8, or 9 months.

### Claim 20 (depends on 1)

The liquid formulation of plasmid DNA according to claim 1, wherein the liquid formulation is prepared in a form of vials, ampules, bottles, or pre-filled syringes.
